COLUMBIA BANKING SYSTEM, INC.
COLUMBIA BANKING SYSTEM, INC. Q3 FY2024 earnings call
October 24, 2024 · fiscal period ended 2024-09
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2024-10-24
Management highlights
- Achieved $270 million gross expense reductions from merger, net savings ~$213 million. - Opened second retail branch in Arizona, planned third and identified fourth; hired teams in various markets. - Piloting applications and onboarding 1,000 associates to CRM tool. - Loan portfolio stable with strong through-the-cycle underwriting; delinquencies improved 22%. - Successful small business campaigns with high retention, broad-based across markets, driving deposit growth and relationship deepening.
Segment performance
Core deposits grew while brokered deposits were reduced by 20% during the quarter. Loans declined $200 million, mostly due to reduced transactional loans. Interest-bearing deposit costs declined to 2.95% in Q3. Provision for credit loss was $29 million, with the leasing portfolio portion at $16 million. Overall allowance for credit loss was 1.17% of total loans. Operating expense in Q3 was $268 million, lower than previous quarters, with planned reinvestments to increase operating expense annualized range to $965 million to $985 million.
Guidance
- Expect continued reduction in interest-bearing deposit costs in Q4. - Operating expense to increase with reinvestments, annualized range $965M-$985M. - Capital ratios expected to continue building, providing allocation flexibility. - Buyback discussions ongoing, with focus on 2025 for potential capital returns to shareholders.
Risks
- Regulatory and interest rate risks affecting deposit costs and balance sheet optimization. - Credit risks from normal business fluctuations and migration of smaller credits affected by higher rates. - Inflationary pressures with expected 3% annual inflation, needing to find efficiencies to offset costs.
Q&A highlights
Q: Just on the core margin, any color on near-term thoughts on core NIM given rate changes and deposit flows?
A: Ron mentioned NIM driver is deposit flows, with $8 billion of CDs and wholesale funding maturing in next 6 months, but normalized deposit flows key.
Q: On the adjusted expense annualized run rate guide, how do you feel about hitting the low end in 4Q?
A: Ronald Farnsworth feels good about hitting low end, with 3% inflation expectation and reinvestments in flight.
Q: On the buyback, any chance of buying back stock soon?
A: Clint Stein says it's ongoing conversations with Board, likely 2025 for capital return window.
Q: On small business campaigns, are they targeted to specific markets?
A: Christopher Merrywell says campaigns are broad-based across all markets.
Q: On organic growth and M&A, thoughts?
A: Clint Stein says focus is on organic growth now, M&A thoughts may change with election and rate clarity.
Q: On loan pipeline and competitive landscape?
A: Tory Nixon says pipeline is stable, with core relationship banking and fee income growth.
Q: On loan yield repricing dynamics?
A: Ronald Farnsworth and Tory Nixon discuss loan yield repricing and new loan yields ranging mid-7s to mid-8s.
Q: On credit and FinPac normalization?
A: Frank Namdar says FinPac normalization improving, expected to drop to 3.5%-4% range.
Q: On securities accretion and beta?
A: Ronald Farnsworth says securities accretion stable, liability sensitivity to mirror up cycle, with deposit beta in mid-50s.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $0.69 | $0.62 | +11.3% | $0.79 |
| Revenue | $496.4M | $481.0M | +3.2% | $524.9M |
Transcript
October 24, 2024Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.